Brief: Ascletis Pharma Updates On Study For Oral 3CLPRO Inhibitor ASC11 For COVID-19
16/01/2023 01:03
Jan 16 (Reuters) - Ascletis Pharma Inc 1672.HK :
* UPDATES ON STUDY FOR ORAL 3CLPRO INHIBITOR ASC11 FOR
COVID-19
* DOSING OF 4 HEALTHY SUBJECTS OF FIRST COHORT IN
MULTIPLE-DOSE
ESCALATION PHASE I CLINICAL TRIAL
Source text for Eikon: ID:nHKS1nCYJD
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management